R
Robert F. Ozols
Researcher at Fox Chase Cancer Center
Publications - 199
Citations - 16984
Robert F. Ozols is an academic researcher from Fox Chase Cancer Center. The author has contributed to research in topics: Ovarian cancer & Carboplatin. The author has an hindex of 65, co-authored 199 publications receiving 16475 citations. Previous affiliations of Robert F. Ozols include Utrecht University.
Papers
More filters
Journal ArticleDOI
Phase III Trial of Carboplatin and Paclitaxel Compared With Cisplatin and Paclitaxel in Patients With Optimally Resected Stage III Ovarian Cancer: A Gynecologic Oncology Group Study
Robert F. Ozols,Brian N. Bundy,Benjamin E. Greer,Jeffrey M. Fowler,Daniel L. Clarke-Pearson,Robert A. Burger,Robert S. Mannel,Koen DeGeest,Ellen M. Hartenbach,Rebecca N. Baergen +9 more
TL;DR: In patients with advanced ovarian cancer, a chemotherapy regimen consisting of carboplatin pluspaclitaxel results in less toxicity, is easier to administer, and is not inferior, when compared with cisplatin plus pac Litaxel.
Journal ArticleDOI
Prognostic Factors for Stage III Epithelial Ovarian Cancer: A Gynecologic Oncology Group Study
William E. Winter,G. Larry Maxwell,Chunqiao Tian,Jay W. Carlson,Robert F. Ozols,Peter G. Rose,Maurie Markman,Deborah K. Armstrong,Franco M. Muggia,William McGuire +9 more
TL;DR: Age, PS, tumor histology, and residual tumor volume were independent predictors of prognosis in patients with stage III EOC and can be used to identify patients with poor prognosis and to design future tailored randomized clinical trials.
Journal ArticleDOI
The anthracycline antineoplastic drugs.
TL;DR: The anthracyclines have become a major therapeutic tool in treating patients with cancer as have the other chemotherapeutic agents used in clinical trials, according to the World Health Organization.
Journal ArticleDOI
Augmentation of adriamycin, melphalan, and cisplatin cytotoxicity in drug-resistant and -sensitive human ovarian carcinoma cell lines by buthionine sulfoximine mediated glutathione depletion
Thomas C. Hamilton,Margaret A. Winker,Karen G. Louie,Gerald Batist,Brent C. Behrens,Takashi Tsuruo,Karen R. Grotzinger,Wilma M. McKoy,Robert C. Young,Robert F. Ozols +9 more
TL;DR: The role of GSH in the expression of sensitivity to agents other than melphalan was examined and the patterns of both primary resistance and cross-resistance were compared following GSH depletion in these cell lines.
Journal Article
Characterization of a cis-Diamminedichloroplatinum(II)-resistant Human Ovarian Cancer Cell Line and Its Use in Evaluation of Platinum Analogues
Brent C. Behrens,Brent C. Behrens,Thomas C. Hamilton,Hidetaka Masuda,Karen R. Grotzinger,Jacqueline Whang-Peng,Karen G. Louie,Turid Knutsen,Wilma M. McKoy,Robert C. Young,Robert F. Ozols +10 more
TL;DR: A2780 and its cisplatin-resistant cell lines may be useful in studying drug resistance mechanisms, in screening new drugs for activity (especially against drug resistant tumors), and in formulating induction and salvage therapies for ovarian cancer.